Detail akcie Biogen Idec online

Business Summary: Biogen Inc. is a global biotechnology company. The Company is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. It is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD), BIIB080 for Alzheimer's disease, tofersen for amyotrophic lateral sclerosis (ALS) and both litifilimab and dapirolizumab pegol for certain forms of lupus.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2022, Biogen Inc revenues decreased 7% to $10.17B. Net income increased 96% to $3.05B. Revenues reflect Rest of World segment decrease of 10% to $4.52B, United States segment decrease of 9% to $3.47B. Net income reflects FV Adjustments of Financial Investments decrease of 68% to $264.7M (expense), Impairment of Intangibles Excl Goodwill decrease of 81% to $119.6M (expense).